Markets
ALNY

Alnylam Pharmaceuticals Inc. Q3 Earnings Summary

October 31, 2024 — 08:22 am EDT

Written by RTTNews.com for RTTNews->

(RTTNews) - Below are the earnings highlights for Alnylam Pharmaceuticals Inc. (ALNY):

Earnings: -$111.57 million in Q3 vs. $147.75 million in the same period last year. EPS: -$0.87 in Q3 vs. $1.15 in the same period last year. Excluding items, Alnylam Pharmaceuticals Inc. reported adjusted earnings of -$64.20 million or -$0.50 per share for the period.

Analysts projected -$0.93 per share Revenue: $420.146 million in Q3 vs. $313.153 million in the same period last year.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

Markets
RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source->

Stocks mentioned

ALNY

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

  • •

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.